LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

Home・Список акций・Bristol-Myers Squibb Co.

Bristol-Myers Squibb Co.

Закрыт

СекторЗдравоохранение

51.16 -0.31

Купить Продать

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

50.3

Макс.

51.47

Ключевые показатели
By Trading Economics
Доход	882M 2.2B
Продажи	-47M 12B
P/E Средняя по отрасли	17.397 77.671
Прибыль на акцию	1.46
Дивидендная доходность	4.76
Рентабельность продаж	17.959
Сотрудники	34,100
EBITDA	1.3B 4.6B

Рекомендации
By TipRanks
Рекомендации	Покупка
Прогноз на 12 месяцев	+3.42% upside

Дивиденды
By Dow Jones
Дивидендная доходность Средняя по отрасли	4.76% 2.35%
Дата следующей выплаты дивидендов	2 февр. 2026 г.
Следующая эксдивидендная дата	2 янв. 2026 г.

Рыночная статистика
By TradingEconomics
Рыночная капитализация	16B 105B
Предыдущая цена открытия	51.47
Предыдущая цена закрытия	51.16

Техническая оценка

By Trading Central

Уверенность

Weak Bearish Evidence

N/A / 50.57 Поддержка и Сопротивление

Bristol-Myers Squibb Co. График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

30 окт. 2025 г., 11:14 UTC

Отчет

Bristol Myers Squibb 3Q Profit Soars, Raises Revenue Guidance

10 окт. 2025 г., 12:32 UTC

Приобретения, слияния, поглощения

Bristol Myers to Buy Orbital Therapeutics for $1.5 Billion

31 июл. 2025 г., 11:14 UTC

Отчет

Bristol Myers Squibb Cuts Full-Year Adjusted View, But Raises Revenue Expectations on Strong 2Q

20 нояб. 2025 г., 13:00 UTC

Отчет

This Drugmaker Is Too Cheap to Ignore. Why Bristol Is a Buy. -- Barrons.com

6 нояб. 2025 г., 20:02 UTC

Приобретения, слияния, поглощения

Biotech M&A Deals Are Trickier Than They Look. Watch the Milestone Payments. -- Barrons.com

30 окт. 2025 г., 16:52 UTC

Приобретения, слияния, поглощения

Novo Nordisk Seeks to Outmuscle Pfizer With $9 Billion Bid for Metsera -- WSJ

30 окт. 2025 г., 16:52 UTC

Приобретения, слияния, поглощения

Metsera Was Previously in Exclusive Talks with Bristol-Myers Squibb, Sources Say -- WSJ

30 окт. 2025 г., 11:32 UTC

Отчет

Bristol Myers Squibb Stock Rises After Solid Earnings. But These Problems Remain. -- Barrons.com

30 окт. 2025 г., 10:59 UTC

Отчет

Bristol Myers Squibb: In Legacy Portfolio, Demand Increased for Eliquis, Which Was More Than Offset by Expected Continued Generic Impact Across Remainder of Legacy Portfolio >BMY

30 окт. 2025 г., 10:59 UTC

Отчет

Bristol Myers Squibb: Revised 2025 Adj EPS Guidance Inclusive of 80c Loss Per Shr Net Impact Related to Acquired IPRD Charges and Licensing Income >BMY

30 окт. 2025 г., 10:59 UTC

Отчет

Bristol Myers Squibb 3Q Adjusted Gross Margin 72.9% >BMY

30 окт. 2025 г., 10:59 UTC

Отчет

Bristol Myers Squibb 3Q U.S. Revenue Rose 1% to $8.33B >BMY

30 окт. 2025 г., 10:59 UTC

Отчет

Bristol Myers Squibb Raises 2025 Rev Guidance to $47.5B-$48B Vs Prior Outlook $46.5B-$47.5B >BMY

30 окт. 2025 г., 10:59 UTC

Отчет

Bristol Myers Squibb: Raised 2025 Rev Guidance Primarily Reflects Continued Strong Performance of Growth Portfolio >BMY

30 окт. 2025 г., 10:59 UTC

Отчет

Bristol Myers Squibb 3Q International Revenue Rose 6% to $3.89B >BMY

30 окт. 2025 г., 10:59 UTC

Отчет

Bristol Myers Squibb: 3Q Growth Portfolio Revenue Increase Primarily Driven by Immuno-Oncology Portfolio, Reblozyl, Camzyos and Breyanzi >BMY

30 окт. 2025 г., 10:59 UTC

Отчет

Bristol Myers Squibb 3Q Legacy Portfolio Rev Fell 12% to $5.37B >BMY

30 окт. 2025 г., 10:59 UTC

Отчет

Bristol Myers Squibb Adjusts 2025 View To Adj EPS $6.40-Adj EPS $6.60 Vs Prior Outlook $6.35-$6.65 >BMY

30 окт. 2025 г., 10:59 UTC

Отчет

Bristol Myers Squibb 3Q Gross Margin 71.9% >BMY

30 окт. 2025 г., 10:59 UTC

Отчет

Bristol Myers Squibb 3Q Growth Portfolio Revenue Rose 18% to $6.86B >BMY

30 окт. 2025 г., 10:59 UTC

Отчет

Bristol Myers Squibb: Latest 3Q Includes Net Impact of Loss of 20c/Shr Due to Acquired IPRD Charges and Licensing Income >BMY

30 окт. 2025 г., 10:59 UTC

Отчет

Bristol Myers Squibb 3Q Adj EPS $1.63 >BMY

30 окт. 2025 г., 10:59 UTC

Отчет

Bristol Myers Squibb 3Q Rev $12.22B >BMY

30 окт. 2025 г., 10:59 UTC

Отчет

Bristol Myers Squibb 3Q EPS $1.08 >BMY

10 окт. 2025 г., 16:19 UTC

Приобретения, слияния, поглощения

Bristol Myers Squibb Buys Private Biotech for $1.5 Billion. The Deal Wave Keeps Going. -- Barrons.com

10 окт. 2025 г., 11:02 UTC

Приобретения, слияния, поглощения

Bristol-Myers Squibb to Pay $1.5B in Cash at Closing to Acquire Orbital >BMY

10 окт. 2025 г., 11:01 UTC

Приобретения, слияния, поглощения

Bristol Myers Squibb Strengthens and Diversifies Cell Therapy Portfolio With Acquisition of Orbital Therapeutics

4 авг. 2025 г., 11:59 UTC

Отчет

BioNTech Stock Rises as Drugmaker Beats Earnings Expectations. -- Barrons.com

31 июл. 2025 г., 11:54 UTC

Отчет

Bristol Myers Cuts Full-Year Adjusted View, But Raises Rev Estimates on Strong 2Q - Update

31 июл. 2025 г., 10:59 UTC

Отчет

Bristol Myers Squibb 2Q Growth Portfolio Revenue Rose 18% to $6.6B >BMY

Сравнение c конкурентами

Изменение цены

Bristol-Myers Squibb Co. Прогноз

Целевая цена

By TipRanks

3.42% рост

Прогноз на 12 месяцев

Средняя 52.38 USD 3.42%

Максимум 68 USD

Минимум 36 USD

Основано на мнении 19 аналитиков Wall Street, спрогнозировавших целевые цены для Bristol-Myers Squibb Co. на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

19 ratings

Покупка

Удержание

Продажа

Основано на мнении 19 аналитиков, присваивавших рейтинги акциям Bristol-Myers Squibb Co. – Данные за последние 3 месяца.

Техническая оценка

By Trading Central

N/A / 50.57Поддержка и Сопротивление

Recent bearish events outweigh bullish events.

All events are bearish.

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

О компании Bristol-Myers Squibb Co.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.